A
14.75
0.90 (6.46%)
| Previous Close | 13.86 |
| Volume | 77,025 |
| Price / Sales | 30.10 |
| Price / Book | 4.09 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,220.88% |
| Diluted EPS (TTM) | -1.62 |
| Quarterly Revenue Growth (YOY) | 118.00% |
| Total Debt/Equity (MRQ) | 106.83% |
| Current Ratio (MRQ) | 1.41 |
| Operating Cash Flow (TTM) | -51.82 M |
| Levered Free Cash Flow (TTM) | -30.61 M |
| Return on Assets (TTM) | -32.84% |
| Return on Equity (TTM) | -103.19% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Adlai Nortye Group Ltd. | Mixed | Bullish |
AIStockmoo Score
-0.7
| Analyst Consensus | NA |
| Insider Activity | -4.0 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | -0.72 |
|
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.25% |
| % Held by Institutions | 0.18% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Superstring Capital Management Lp | 30 Jun 2026 | 552,501 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| YE XIAOFENG | - | 15.06 | -5,667 | -85,345 |
| Aggregate Net Quantity | -5,667 | |||
| Aggregate Net Value ($) | -85,345 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 15.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| YE XIAOFENG | Officer | 26 Aug 2026 | Sell (-) | 5,667 | 15.06 | 85,345 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |